STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
Also reported by 2 other outlets
- Argenx's study flop in Sjögren's overshadows a win in celiac disease endpoints.news
- Argenx falls as Sjögren’s setback offsets celiac drug progress biopharmadive.com
